Jones Christopher David, Guiot Luke, Samy Mike, Gorman Mark, Tehrani Hamid
Glasgow Royal Infirmary , Merseyside, UK.
University Hospital Ayr , Merseyside, UK.
Dermatol Reports. 2015 May 21;7(2):5880. doi: 10.4081/dr.2015.5880.
Keloid scars are pathological scars, which develop as a result of exaggerated dermal tissue proliferation following cutaneous injury and often cause physical, psychological and cosmetic problems. Various theories regarding keloidogenesis exist, however the precise pathophysiological events remain unclear. Many different treatment modalities have been implicated in their management, but currently there is no entirely satisfactory method for treating all keloid lesions. We review a number of different chemotherapeutic agents which have been proposed for the treatment of keloid and hypertrophic scars while giving insight into some of the novel chemotherapeutic drugs which are currently being investigated. Non-randomized trials evaluating the influence of different chemotherapeutic agents, such as 5-fluorouracil (5-FU); mitomycin C; bleomycin and steroid injection, either alone or in combination with other chemotherapeutic agents or alternative treatment modalities, for the treatment of keloids were identified using a predefined PubMed search strategy. Twenty seven papers were identified. Scar improvement ≥50% was found in the majority of cases treated with 5-FU, with similar results found for mitomycin C, bleomycin and steroid injection. Combined intralesional 5-FU and steroid injection produced statistically significant improvements when compared to monotherapy. Monotherapy recurrence rates ranged from 0-47% for 5-FU, 0-15% for bleomycin and 0-50% for steroid injection. However, combined therapy in the form of surgical excision and adjuvant 5-FU or steroid injections demonstrated lower recurrence rates; 19% and 6% respectively. Currently, most of the literature supports the use of combination therapy (usually surgery and adjuvant chemotherapy) as the mainstay treatment of keloids, however further investigation is necessary to determine success rates over longer time frames. Furthermore, there is the potential for novel therapies, but further investigation is required to elucidate their true efficacy.
瘢痕疙瘩是病理性瘢痕,由皮肤损伤后真皮组织过度增生形成,常导致生理、心理和美容问题。关于瘢痕疙瘩形成有多种理论,但确切的病理生理过程仍不清楚。多种不同的治疗方式用于其治疗,但目前尚无完全令人满意的方法来治疗所有瘢痕疙瘩病变。我们综述了一些已被提议用于治疗瘢痕疙瘩和增生性瘢痕的不同化疗药物,同时深入探讨了目前正在研究的一些新型化疗药物。使用预定义的PubMed搜索策略,确定了评估不同化疗药物(如5-氟尿嘧啶(5-FU)、丝裂霉素C、博来霉素和类固醇注射)单独或与其他化疗药物或替代治疗方式联合用于治疗瘢痕疙瘩的非随机试验。共确定了27篇论文。在大多数接受5-FU治疗的病例中发现瘢痕改善≥50%,丝裂霉素C、博来霉素和类固醇注射也有类似结果。与单一疗法相比,病灶内联合注射5-FU和类固醇产生了统计学上的显著改善。单一疗法的复发率为:5-FU为0 - 47%,博来霉素为0 - 15%,类固醇注射为0 - 50%。然而,手术切除联合辅助使用5-FU或类固醇注射的联合疗法复发率较低,分别为19%和6%。目前,大多数文献支持使用联合疗法(通常是手术和辅助化疗)作为瘢痕疙瘩的主要治疗方法,但需要进一步研究以确定更长时间内的成功率。此外,新型疗法有潜力,但需要进一步研究以阐明其真正疗效。